Glycemic management in type 2 diabetes mellitus has become increasingly complex and, to some extent, controversial, with a widening array of pharmacological agents now available, mounting concerns about their potential adverse effects and new uncertainties regarding the benefits of intensive glycemic control on macrovascular complications. Many clinicians are therefore perplexed as to the optimal strategies for their patients. As a consequence, the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) convened a joint task force to examine the evidence and develop recommendations for antihyperglycemic therapy in nonpregnant adults with type 2 diabetes. Several guideline documents have been developed by members of these two organizations and by other societies and federations. However, an update was deemed necessary because of contemporary information on the benefits/risks of glycemic control, recent evidence concerning efficacy and safety of several new drug classes, the withdrawal/restriction of others, and increasing calls for a move toward more patient-centered care.

This statement has been written incorporating the best available evidence and, where solid support does not exist, using the experience and insight of the writing group, incorporating an extensive review by additional experts (acknowledged below). The document refers

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Silvio E. Inzucchi, MD, Richard M. Bergenstal, MD, John B. Buse, MD, PhD, Michaela Diamant, MD, PhD, Ele Ferrannini, MD, Michael Nauck, MD, Anne L. Peters, MD, Apostolos Tsapas, MD, PhD, Richard Wender, MD, and David R. Matthews, MD, DPhil

Reprinted with permission from Diabetes Care 35:1364–1379, 2012
<table>
<thead>
<tr>
<th>Class</th>
<th>Compound(s)</th>
<th>Cellular mechanism</th>
<th>Primary physiological action(s)</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biguanides</td>
<td>Metformin</td>
<td>Activates AMP-kinase</td>
<td>↓ Hepatic glucose production</td>
<td>Extensive experience</td>
<td>Gastrointestinal side effects (diarrhea, abdominal cramping)</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No weight gain</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No hypoglycemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Likely ↓ CVD events (UKPDS)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfonylureas</td>
<td>2nd generation</td>
<td>Closes $K_{ATP}$ channels on β-cell plasma membranes</td>
<td>↑ Insulin secretion</td>
<td>Extensive experience</td>
<td>Hypoglycemia</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>Glyburide/ glibenclamide</td>
<td></td>
<td></td>
<td></td>
<td>Weight gain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glipizide</td>
<td></td>
<td></td>
<td>Microvascular risk (UKPDS)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glimepiride</td>
<td></td>
<td></td>
<td>Hypoglycemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meglitinides (glinides)</td>
<td>Repaglinide</td>
<td>Closes $K_{ATP}$ channels on β-cell plasma membranes</td>
<td>↑ Insulin secretion</td>
<td>Extensive experience</td>
<td>Weight gain</td>
<td>High</td>
</tr>
<tr>
<td></td>
<td>Nateglinide</td>
<td></td>
<td></td>
<td>↓ Postprandial glucose excursions</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dosing flexibility</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thiazolidinediones</td>
<td>Pioglitazone</td>
<td>Activates the nuclear transcription factor PPAR-γ</td>
<td>↑ Insulin sensitivity</td>
<td>No hypoglycemia</td>
<td>Weight gain</td>
<td>High&lt;sup&gt;e&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Rosiglitazone</td>
<td></td>
<td></td>
<td>Durability</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>↑ HDL-C</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>↓ Triglycerides (pioglitazone)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>↓ CVD events (ProACTIVE, pioglitazone)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>α-Glucosidase inhibitors&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Acarbose</td>
<td>Inhibits intestinal α-glucosidase digestion/absorption</td>
<td>No hypoglycemia</td>
<td>Postprandial glucose excursions</td>
<td>Generally modest HbA&lt;sub&gt;1c&lt;/sub&gt; efficacy</td>
<td>Moderate</td>
</tr>
<tr>
<td></td>
<td>Miglitol</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Voglibose&lt;sup&gt;b,d&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>Limited use in the U.S./Europe. <sup>b</sup>Not licensed in the U.S. <sup>c</sup>Prescribing highly restricted in the U.S.; withdrawn in Europe. <sup>d</sup>Not licensed in Europe. To be available as a generic product in 2012, with expected significant reductions in cost. <sup>e</sup>Depends on type (analogs > human insulins) and dosage. CKD, chronic kidney disease; CVD, cardiovascular disease; DPP-4, dipeptidyl peptidase 4; GIP, glucose-dependent insulinotropic peptide; GLP-1, glucagon-like peptide 1; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; PPAR, peroxisome proliferator–activated receptor; ProACTIVE, Prospective Pioglitazone Clinical Trial in Macrovascular Events; STOP-NIDDM, Study to Prevent Non-Insulin-Dependent Diabetes Mellitus; UKPDS, UK Prospective Diabetes Study.<sup>29–33</sup>

continued on p. 156
to glycemic control; yet this clearly needs to be pursued within a multifactorial risk reduction framework. This stems from the fact that patients with type 2 diabetes are at increased risk of cardiovascular morbidity and mortality; the aggressive management of cardiovascular risk factors (blood pressure and lipid therapy, antiplatelet treatment, and smoking cessation) is likely to have even greater benefits.

These recommendations should be considered within the context of the needs, preferences, and tolerances

<table>
<thead>
<tr>
<th>Class</th>
<th>Compound(s)</th>
<th>Cellular mechanism</th>
<th>Primary physiological action(s)</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>DPP-4 inhibitors</td>
<td>• Sitagliptin&lt;br&gt;• Vildagliptin&lt;br&gt;• Saxagliptin&lt;br&gt;• Linagliptin&lt;br&gt;• Alogliptin&lt;sup&gt;b,d&lt;/sup&gt;</td>
<td>Inhibits DPP-4 activity, increasing postprandial active incretin (GLP-1, GIP) concentrations</td>
<td>• ↑ Insulin secretion (glucose-dependent)&lt;br&gt;• ↓ Glucagon secretion (glucose-dependent)</td>
<td>• No hypoglycemia&lt;br&gt;• Well tolerated</td>
<td>• Generally modest HbA&lt;sub&gt;1c&lt;/sub&gt; efficacy&lt;br&gt;• Urticaria/angioedema&lt;br&gt;• ? Pancreatitis</td>
<td>High</td>
</tr>
<tr>
<td>Bile acid sequestrants&lt;sup&gt;a&lt;/sup&gt;</td>
<td>• Colesevelam</td>
<td>Binds bile acids in intestinal tract, increasing hepatic bile acid production; ? activation of farnesoid X receptor (FXR) in liver</td>
<td>• Unknown&lt;br&gt;• ? Hepatic glucose production&lt;br&gt;• ? ↑ Incretin levels</td>
<td>• No hypoglycemia&lt;br&gt;• ↓ LDL-C</td>
<td>• Generally modest HbA&lt;sub&gt;1c&lt;/sub&gt; efficacy&lt;br&gt;• Constipation&lt;br&gt;• ↑ Triglycerides&lt;br&gt;• May ↓ absorption of other medications</td>
<td>High</td>
</tr>
<tr>
<td>Dopamine-2 agonists&lt;sup&gt;b&lt;/sup&gt;</td>
<td>• Bromocriptine (quick-release)&lt;sup&gt;d&lt;/sup&gt;</td>
<td>Activates dopaminergic receptors</td>
<td>• Modulates hypothalamic regulation of metabolism&lt;br&gt;• ↑ Insulin sensitivity</td>
<td>• No hypoglycemia&lt;br&gt;• ↓ CVD events (Cycloset Safety Trial)</td>
<td>• Generally modest HbA&lt;sub&gt;1c&lt;/sub&gt; efficacy&lt;br&gt;• Dizziness/syncope&lt;br&gt;• Nausea&lt;br&gt;• Fatigue&lt;br&gt;• Rhinitis</td>
<td>High</td>
</tr>
<tr>
<td>GLP-1 receptor agonists</td>
<td>• Exenatide&lt;br&gt;• Exenatide extended release&lt;br&gt;• Liraglutide</td>
<td>Activates GLP-1 receptors</td>
<td>• ↑ Insulin secretion (glucose-dependent)&lt;br&gt;• ↓ Glucagon secretion (glucose-dependent)&lt;br&gt;• Slows gastric emptying&lt;br&gt;• ↑ Satiety</td>
<td>• No hypoglycemia&lt;br&gt;• Weight reduction&lt;br&gt;• ? Potential for improved β-cell mass/function&lt;br&gt;• ? Cardiovascular protective actions</td>
<td>• Gastrointestinal side effects (nausea/vomiting)&lt;br&gt;• ? Acute pancreatitis&lt;br&gt;• C-cell hyperplasia/medullary thyroid tumors in animals&lt;br&gt;• Injectable&lt;br&gt;• Training requirements</td>
<td>High</td>
</tr>
</tbody>
</table>

<sup>a</sup>Limited use in the U.S./Europe. <sup>b</sup>Not licensed in the U.S. <sup>c</sup>Prescribing highly restricted in the U.S.; withdrawn in Europe. <sup>d</sup>Not licensed in Europe. <sup>e</sup>To be available as a generic product in 2012, with expected significant reductions in cost. <sup>f</sup>Depends on type (analogs > human insulins) and dosage. CKD, chronic kidney disease; CVD, cardiovascular disease; DPP-4, dipeptidyl peptidase 4; GIP, glucose-dependent insulinotropic peptide; GLP-1, glucagon-like peptide 1; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; PPAR, peroxisome proliferator–activated receptor; ProACTIVE, Prospective Pioglitazone Clinical Trial in Macrovascular Events; STOP-NIDDM, Study to Prevent Non-Insulin-Dependent Diabetes Mellitus; UKPDS, UK Prospective Diabetes Study.29–33

continued on p. 157
of each patient; individualization of treatment is the cornerstone of success. Our recommendations are less prescriptive than and not as algorithmic as prior guidelines. This follows from the general lack of comparative-effectiveness research in this area. Our intent is therefore to encourage an appreciation of the variable and progressive nature of type 2 diabetes, the specific role of each drug, the patient and disease factors that drive clinical decision making, and the constraints imposed by age and comorbidity. The implementation of these guidelines will require thoughtful clinicians to integrate current evidence with other constraints and imperatives in the context of patient-specific factors.

### Patient-Centered Approach
Evidence-based advice depends on the existence of primary source evidence. This emerges only from clinical trial results in highly selected patients, using limited strategies. It does not address the range of choices available, or the order of use of additional therapies. Even if such evidence were available, the data would show median responses and not address the vital question of who responded to which therapy and why. Patient-centered care is defined as an approach to “providing care that is respectful of and responsive to individual patient preferences, needs, and values and ensuring that patient values guide all clinical decisions.” This should be the organizing principle underlying health care for individuals with any chronic disease, but given our uncertainties in terms of choice or sequence of therapy, it is particularly appropriate in type 2 diabetes. Ultimately, it is patients who make the final decisions regarding their lifestyle choices and, to some degree, the pharmaceutical interventions they use; their implementation occurs in the context of the patients’ real lives and relies on the consumption of resources (both public and private).

Patient involvement in the medical decision making constitutes one of the core principles of evidence-based medicine, which mandates the synthesis of best available evidence from the literature with the clinician’s expertise and patient’s own inclinations. During the clinical encounter, the patient’s preferred level of involvement should be gauged and therapeutic choices explored, potentially with the utilization of decision aids.

### Table 1. Properties of Currently Available Glucose-Lowering Agents That May Guide Treatment Choice in Individual Patients With Type 2 Diabetes Mellitus, continued from p. 156

<table>
<thead>
<tr>
<th>Class</th>
<th>Compound(s)</th>
<th>Cellular mechanism</th>
<th>Primary physiological action(s)</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amylin mimetics</td>
<td>• Pramlintide</td>
<td>Activates amylin receptors</td>
<td>• ↓ Glucagon secretion</td>
<td>• ↓ Postprandial glucose excursions</td>
<td>• Generally modest HbA1c efficacy</td>
<td>High</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• Slows gastric emptying</td>
<td>• Weight reduction</td>
<td>• Gastrointestinal side effects</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>• ↑ Satiety</td>
<td></td>
<td>(nausea/vomiting)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Hypoglycemia</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Weight gain</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• ? Mitogenic effects</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Injectable</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Training requirements</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>“Stigma” (for patients)</td>
<td></td>
</tr>
<tr>
<td>Insulins</td>
<td>• Human NPH</td>
<td>Activates insulin receptors</td>
<td>• ↑ Glucose disposal</td>
<td>• Universally effective</td>
<td>• Hypoglycemia</td>
<td>Variable</td>
</tr>
<tr>
<td></td>
<td>• Human Regular</td>
<td></td>
<td>• ↓ Hepatic glucose production</td>
<td>• Theoretically unlimited efficacy</td>
<td>• Weight gain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Lispro</td>
<td></td>
<td></td>
<td>• ↓ Microvascular risk (UKPDS)</td>
<td>• ? Mitogenic effects</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Aspart</td>
<td></td>
<td></td>
<td></td>
<td>• Injectable</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Glulisine</td>
<td></td>
<td></td>
<td></td>
<td>• Training requirements</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Glargine</td>
<td></td>
<td></td>
<td></td>
<td>“Stigma” (for patients)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Detemir</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Premixed (several types)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Limited use in the U.S./Europe. *Not licensed in the U.S. *Prescribing highly restricted in the U.S.; withdrawn in Europe. *Not licensed in Europe. *To be available as a generic product in 2012, with expected significant reductions in cost. *Depends on type (analogs > human insulins) and dosage. CKD, chronic kidney disease; CVD, cardiovascular disease; DPP-4, dipeptidyl peptidase 4; GIP, glucose-dependent insulino tropic peptide; GLP-1, glucagon-like peptide 1; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; PPAR, peroxisome proliferator-activated receptor; ProACTIVE, Prospective Pioglitazone Clinical Trial in Macrovascular Events; STOP-NIDDM, Study to Prevent Non-Insulin-Dependent Diabetes Mellitus; UKPDS, UK Prospective Diabetes Study.26–29
consensus on the therapeutic course of action. There is good evidence supporting the effectiveness of this approach. Importantly, engaging patients in health care decisionsmay enhance adherence to therapy.

**Background**

**Epidemiology and health care impact**

Both the prevalence and incidence of type 2 diabetes are increasing worldwide, particularly in developing countries, in conjunction with increased obesity rates and westernization of lifestyle. The attendant economic burden for health care systems is skyrocketing, owing to the costs associated with treatment and diabetes complications. Type 2 diabetes remains a leading cause of cardiovascular disorders, blindness, end-stage renal failure, amputations, and hospitalizations. It is also associated with increased risk of cancer, serious psychiatric illness, cognitive decline, chronic liver disease, accelerated arthritis, and other disabling or deadly conditions. Effective management strategies are of obvious importance.

**Relationship of glycemic control to outcomes**

It is well established that the risk of microvascular and macrovascular complications is related to glycemia, as measured by HbA1c; this remains a major focus of therapy. Prospective randomized trials have documented reduced rates of microvascular complications in type 2 diabetic patients treated to lower glycemic targets. In the UK Prospective Diabetes Study (UKPDS), patients with newly diagnosed type 2 diabetes were randomized to two treatment policies. In the standard group, lifestyle intervention was the mainstay with pharmacological therapy used only if hyperglycemia became severe. In the more intensive treatment arm, patients were randomly assigned to either a sulfonylurea or insulin, with a subset of overweight patients randomized to metformin. The overall HbA1c achieved was 0.9% lower in the intensive policy group compared with the conventional policy arm (7.0% vs. 7.9%). Associated with this difference in glycemic control was a reduction in the risk of microvascular complications (retinopathy, nephropathy, neuropathy) with intensive therapy. A trend toward reduced rates of myocardial infarction in this group did not reach statistical significance. By contrast, substantially fewer metformin-treated patients experienced myocardial infarction, diabetes-related and all-cause mortality, despite a mean HbA1c only 0.6% lower than the conventional policy group. The UKPDS 10-year follow-up demonstrated that the relative benefit of having been in the intensive management policy group was maintained over a decade, resulting in the emergence of statistically significant benefits on cardiovascular disease (CVD) end points and total mortality in those initially assigned to sulfonylurea/insulin, and persistence of CVD benefits with metformin, in spite of the fact that the mean HbA1c levels between the groups converged soon after the randomized component of the trial had concluded.

In 2008, three shorter-term studies (Action to Control Cardiovascular Risk in Diabetes (ACCORD), Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE), Veterans Affairs Diabetes Trial (VADT)) reported the effects of two levels of glycemic control on cardiovascular end points in middle-aged and older individuals with well-established type 2 diabetes at high risk for cardiovascular events. ACCORD and VADT aimed for an HbA1c < 6.0% using complex combinations of oral agents and...
Position Statement

Antihyperglycemic Therapy

Glycemic targets
The ADA’s “Standards of Medical Care in Diabetes” recommends lowering HbA1c to < 7.0% in most patients to reduce the incidence of microvascular disease. This can be achieved with a mean plasma glucose of ~ 8.3–8.9 mmol/L (150–160 mg/dL); ideally, fasting and premeal glucose should be maintained at < 7.2 mmol/L (< 130 mg/dL) and the postprandial glucose at < 10 mmol/L (< 180 mg/dL). More stringent HbA1c targets (e.g., 6.0–6.5%) might be considered in selected patients (with short disease duration, long life expectancy, no significant CVD) if this can be achieved without significant hypoglycemia or other adverse effects of treatment.

The accumulated results from the aforementioned type 2 diabetes cardiovascular trials suggest that not everyone benefits from aggressive glucose management. It follows that it is important to individualize treatment targets. The elements that may guide the clinician in choosing an HbA1c target for a specific patient are shown in Figure 1. As mentioned earlier, the desires and values of the patient should also be considered, since the achievement of any degree of glucose control requires active participation and commitment.

Indeed, any target could reflect an agreement between patient and clinician. An important related concept is that the ease with which more intensive targets are reached influences treatment decisions; logically, lower targets are attractive if they can be achieved with less complex regimens and no or minimal adverse effects. Importantly, utilizing the percentage of diabetic patients who are achieving an HbA1c < 7.0% as a quality indicator, as promulgated by various health care organizations,

Overview of the pathogenesis of type 2 diabetes
Any rise in glycemia is the net result of glucose influx exceeding glucose outflow from the plasma compartment. In the fasting state, hyperglycemia is directly related to increased hepatic glucose production. In the postprandial state, further glucose excursions result from the combination of insufficient suppression of this glucose output and defective insulin stimulation of glucose disposal in target tissues, mainly skeletal muscle. Once the renal tubular transport maximum for glucose is exceeded, glycosuria curbs, though does not prevent, further hyperglycemia.

Abnormal islet cell function is a key and requisite feature of type 2 diabetes. In early disease stages, insulin production is normal or increased in absolute terms, but disproportionately low for the degree of insulin sensitivity, which is typically reduced. However, insulin kinetics, such as the ability of the pancreatic β-cell to release adequate hormone in phase with rising glycemia, are profoundly compromised. This functional islet incompetence is the main quantitative determinant of hyperglycemia and progresses over time. In addition, in type 2 diabetes, pancreatic α-cells hypersecrete glucagon, further promoting hepatic glucose production. Importantly, islet dysfunction is not necessarily irreversible. Enhancing insulin action relieves β-cell secretory burden, and any intervention that improves glycemia—from energy restriction to, most strikingly, bariatric surgery—can ameliorate β-cell dysfunction to an extent. More recently recognized abnormalities in the incretin system (represented by the gut hormones, glucagon-like peptide 1 [GLP-1], and glucose-dependent insulinotropic peptide [GIP]) are also found in type 2 diabetes, but it remains unclear whether these constitute primary or secondary defects.

In most patients with type 2 diabetes, especially the obese, insulin resistance in target tissues (liver, muscle, adipose tissue, myocardium) is a prominent feature. This results in both glucose overproduction and underutilization. Moreover, an increased delivery of fatty acids to the liver favors their oxidation, which contributes to increased gluconeogenesis, whereas the absolute overabundance of lipids promotes hepatosteatosis.

Antihyperglycemic agents are directed at one or more of the pathophysiologic defects of type 2 diabetes, or modify physiologic processes relating to appetite or to nutrient absorption or excretion. Ultimately, type 2 diabetes is a disease that is heterogeneous in both pathogenesis and in clinical manifestation—a point to be considered when determining the optimal therapeutic strategy for individual patients.

Antihyperglycemic Therapy

Glycemic targets
The ADA’s “Standards of Medical Care in Diabetes” recommends
is inconsistent with the emphasis on individualization of treatment goals.

**Therapeutic options**

**Lifestyle.** Interventions designed to impact an individual’s physical activity levels and food intake are critical parts of type 2 diabetes management. All patients should receive standardized general diabetes education (individual or group, preferably using an approved curriculum), with a specific focus on dietary interventions and the importance of increasing physical activity. While encouraging therapeutic lifestyle change is important at diagnosis, periodic counseling should also be integrated into the treatment program.

Weight reduction, achieved through dietary means alone or with adjunctive medical or surgical intervention, improves glycemic control and other cardiovascular risk factors. Modest weight loss (5–10%) contributes meaningfully to achieving improved glucose control. Accordingly, establishing a goal of weight reduction, or at least weight maintenance, is recommended.

Dietary advice must be personalized. Patients should be encouraged to eat healthy foods that are consistent with the prevailing population-wide dietary recommendations and with an individual’s preferences and culture. Foods high in fiber (such as vegetables, fruits, whole grains, and legumes), low-fat dairy products, and fresh fish should be emphasized. High-energy foods, including those rich in saturated fats, and sweet desserts and snacks should be eaten less frequently and in lower amounts. Patients who eventually lose and keep weight off usually do so after numerous cycles of weight loss and relapse. The health care team should remain nonjudgmental but persistent, revisiting and encouraging therapeutic lifestyle changes frequently, if needed.

As much physical activity as possible should be promoted, ideally aiming for at least 150 min/week of moderate activity including aerobic, resistance, and flexibility training. In older individuals, or those with mobility challenges, so long as tolerated from a cardiovascular standpoint, any increase in activity level is advantageous.

At diagnosis, highly motivated patients with HbA1c already near target (e.g., <7.5%) could be given the opportunity to engage in lifestyle change for a period of 3–6 months before embarking on pharmacotherapy (usually metformin). Those with moderate hyperglycemia or in whom lifestyle changes are anticipated to be unsuccessful should be promptly started on an antihyperglycemic agent (also usually metformin) at diagnosis, which can later be modified or possibly discontinued if lifestyle changes are successful.

**Oral agents and noninsulin injectables.** Important properties of antihyperglycemic agents that play a role in the choice of drug(s) in individual patients are summarized in Table 1. Ultimately, the aims of controlling glycemia are to avoid acute osmotic symptoms of hyperglycemia, to avoid instability in blood glucose over time, and to prevent/delay the development of diabetes complications without adversely affecting quality of life. Information on whether specific agents have this ability is incomplete; an answer to these questions requires long-term, large-scale clinical trials—not available for most drugs. Effects on surrogate measures for glycemic control (e.g., HbA1c) generally reflect changes in the probability of developing microvascular disease but not necessarily macrovascular complications. Particularly from a patient standpoint, stability of metabolic control over time may be another specific goal.

Metformin, a biguanide, remains the most widely used first-line type 2 diabetes drug; its mechanism of action predominately involves reducing hepatic glucose production. It is generally considered weight-neutral with chronic use and does not increase the risk of hypoglycemia. Metformin is associated with initial gastrointestinal side effects, and caution is advised to avoid its use in patients at risk for lactic acidosis (e.g., in advanced renal insufficiency, alcoholism), a rare complication of therapy. As noted earlier, there may be some cardiovascular benefits from this drug, but the clinical trial data are not robust.

The oldest oral agent class is the sulfonylurea insulin secretagogues. Through the closure of ATP-sensitive potassium channels on β-cells, these drugs stimulate insulin release. While effective in controlling glucose levels, their use is associated with modest weight gain and risk of hypoglycemia. In addition, studies have demonstrated a secondary failure rate that may exceed other drugs, ascribed to an exacerbation of islet dysfunction. Shorter-acting secretagogues, the meglitinides (or glinides), stimulate insulin release through similar mechanisms but may be associated with less hypoglycemia. They require more frequent dosing, however.

Thiazolidinediones (TZDs) are peroxisome proliferator–activated receptor γ activators that improve insulin sensitivity in skeletal muscle and reduce hepatic glucose produc-
position, They do not increase the risk of hypoglycemia and may be more durable in their effectiveness than sulfonylureas and metformin. Pioglitazone appeared to have a modest benefit on cardiovascular events as a secondary outcome in one large trial involving patients with overt macrovascular disease. Another agent of this class, rosiglitazone, is no longer widely available owing to concerns of increased myocardial infarction risk. Pioglitazone has recently been associated with a possible increased risk of bladder cancer. Recognized side effects of TZDs include weight gain, fluid retention leading to edema and/or heart failure in predisposed individuals, and increased risk of bone fractures.

Drugs focused on the incretin system have been introduced more recently. The injectable GLP-1 receptor agonists mimic the effects of endogenous GLP-1, thereby stimulating pancreatic insulin secretion in a glucose-dependent fashion, suppressing pancreatic glucagon output, slowing gastric emptying, and decreasing appetite. Their main advantage is weight loss, which is modest in most patients but can be significant in some. A limiting side effect is nausea and vomiting, particularly early in the course of treatment. Concerns regarding an increased risk of pancreatitis remain unresolved. The oral dipeptidyl peptidase 4 (DPP-4) inhibitors enhance circulating concentrations of active GLP-1 and GIP. Their major effect appears to be in the regulation of insulin and glucagon secretion; they are weight neutral. Typically, neither of the incretin-based classes cause hypoglycemia by themselves.

Two agents that are used infrequently in the U.S. and Europe are the α-glucosidase inhibitors (AGIs), which retard gut carbohydrate absorption, and colesvelam, a bile acid sequestrant whose mechanism of glucose-lowering action remains poorly understood and whose major additional benefit is LDL-cholesterol reduction. Both have gastrointestinal effects, mainly flatulence with AGIs and constipation with colesvelam. The dopamine agonist bromocriptine is only available in the U.S. as an antihyperglycemic agent. Its mechanism of action and precise role are unclear. The amylin agonist, pramlintide, is typically reserved for patients treated with intensive insulin therapy, usually in type 1 diabetes mellitus; it decreases postprandial glucose excursions by inhibiting glucagon secretion and slowing gastric emptying.

The glucose-lowering effectiveness of noninsulin pharmacological agents is said to be high for metformin, sulfonylureas, TZDs, and GLP-1 agonists (expected HbA₁c reduction = 1.0–1.5%), and generally lower for meglitinides, DPP-4 inhibitors, AGIs, colesvelam, and bromocriptine (~0.5–1.0%). However, older drugs have typically been tested in clinical trial participants with higher baseline HbA₁c, which is itself associated with greater treatment emergent glycemic reductions, irrespective of therapy type. In head-to-head studies, any differential effects on glucose control are small. So agent- and patient-specific properties, such as dosing frequency, side-effect profiles, cost, and other benefits often guide their selection.

Insulin. Due to the progressive β-cell dysfunction that characterizes type 2 diabetes, insulin replacement therapy is frequently required. Importantly, most patients maintain some endogenous insulin secretion even in late stages of disease. Accordingly, the more complex and intensive strategies of type 1 diabetes are not typically necessary.

Ideally, the principle of insulin use is the creation of as normal a glycemic profile as possible without unacceptable weight gain or hypoglycemia. As initial therapy, unless the patient is markedly hyperglycemic and/or symptomatic, a “basal” insulin alone is typically added. Basal insulin provides relatively uniform insulin coverage throughout the day and night, mainly to control blood glucose by suppressing hepatic glucose production in between meals and during sleep. Either intermediate-acting (neutral protamine Hagedorn [NPH]) or long-acting (insulin glargine [A21Gly,B31Arg,B32Arg human insulin] or insulin detemir [B29Lys (ε-tetradecanoyl),desB30 human insulin]) formulations may be used. The latter two are associated with modestly less overnight hypoglycemia (insulin glargine, insulin detemir) than NPH and possibly slightly less weight gain (insulin detemir), but are more expensive. Of note, the dosing of these basal insulin analogs may differ, with most comparative trials showing a higher average unit requirement with insulin detemir.

Although the majority of patients with type 2 diabetes requiring insulin therapy can be successfully treated with basal insulin alone, some, because of progressive diminution in their insulin secretory capacity, will require prandial insulin therapy with shorter-acting insulins. This is typically provided in the form of the rapid insulin analogs, insulin lispro (B28Lys,B29Pro human insulin), insulin aspart (B28Asp human insulin), or insulin glulisine (B3Lys,B29Glu human insulin), which may be dosed just before the meal. They result in better postprandial glucose control than the less costly human regular insulin, whose pharmacokinetic profile makes it less attractive in this setting.

Ideally, an insulin treatment program should be designed specifically for an individual patient, to match the supply of insulin to his or her dietary/exercise habits and prevailing glucose trends, as revealed through self-monitoring. Anticipated glucose-lowering effects should be balanced with the convenience of the regimen, in the context of an individual’s specific therapy goals (Figure 1).

Proper patient education regarding glucose monitoring, insulin injection technique, insulin storage, recognition/treatment of hypoglycemia, and “sick day” rules is imperative. Where available, certified diabetes educators can be invaluable in guiding the patient through this process.

Implementation strategies

Initial drug therapy. It is generally agreed that metformin, if not contraindicated and if tolerated, is the preferred and most cost-effective first agent (Figure 2 and Supplementary
Figure 2. Antihyperglycemic therapy in type 2 diabetes: general recommendations. Moving from the top to the bottom of the figure, potential sequences of antihyperglycemic therapy. In most patients, begin with lifestyle changes; metformin monotherapy is added at, or soon after, diagnosis (unless there are explicit contraindications). If the HbA1c target is not achieved after ~3 months, consider one of the five treatment options combined with metformin: a sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, or basal insulin. (The order in the chart is determined by historical introduction and route of administration and is not meant to denote any specific preference.) Choice is based on patient and drug characteristics, with the over-riding goal of improving glycemic control while minimizing side effects. Shared decision making with the patient may help in the selection of therapeutic options. The figure displays drugs commonly used both in the U.S. and/or Europe. Rapid-acting secretagogues (meglitinides) may be used in place of sulfonylureas. Other drugs not shown (α-glucosidase inhibitors, colesevelam, dopamine agonists, pramlintide) may be used where available in selected patients but have modest efficacy and/or limiting side effects. In patients intolerant of, or with contraindications for, metformin, select initial drug from other classes depicted and proceed accordingly. In this circumstance, while published trials are generally lacking, it is reasonable to consider three-drug combinations other than metformin. Insulin is likely to be more effective than most other agents as a third-line therapy, especially when HbA1c is very high (e.g., ≥9.0%). The therapeutic regimen should include some basal insulin before moving to more complex insulin strategies (Figure 3). Dashed arrow line on the left-hand side of the figure denotes the option of a more rapid progression from a two-drug combination directly to multiple daily insulin doses, in those patients with severe hyperglycemia (e.g., HbA1c ≥10.0–12.0%), DPP-4-i, DPP-4 inhibitor; Fx’s, bone fractures; GI, gastrointestinal; GLP-1-RA, GLP-1 receptor agonist; HF, heart failure; SU, sulfonylurea. *Consider beginning at this stage in patients with very high HbA1c (e.g., ≥9 %). †Consider rapid-acting, nonsulfonylurea secretagogues (meglitinides) in patients with irregular meal schedules or who develop late postprandial hypoglycemia on sulfonylureas. See Table 1 for additional potential adverse effects and risks, under “Disadvantages.” ‡Usually a basal insulin (NPH, glargine, detemir) in combination with noninsulin agents. §Certain noninsulin agents may be continued with insulin (see text). Refer to Figure 3 for details on regimens. Consider beginning at this stage if patient presents with severe hyperglycemia (≥16.7–19.4 mmol/L [≥300–350 mg/dL]; HbA1c ≥10.0–12.0%) with or without catabolic features (weight loss, ketosis, etc.).
therapy should be strongly considered in drug selection.20,21 (See effects, potential for weight gain and hypoglycemia should play a major role in drug selection.20,21 (See characteristics, susceptibilities to side effects and hypoglycemia should be strongly considered from the outset. Such treatment is mandatory when catabolic features are exhibited or, of course, if ketonuria is demonstrated, the latter reflecting profound insulin deficiency. Importantly, unless there is evidence of type 1 diabetes, once symptoms are relieved, glucotoxicity resolved, and the metabolic state stabilized, it may be possible to taper insulin partially or entirely, transferring to noninsulin antihyperglycemic agents, perhaps in combination.

If metformin cannot be used, another oral agent could be chosen, such as a sulfonylurea/glinide, pioglitazone, or a DPP-4 inhibitor; in occasional cases where weight loss is seen as an essential aspect of therapy, initial treatment with a GLP-1 receptor agonist might be useful. Where available, less commonly used drugs (AGIs, colesevelam, bromocriptine) might also be considered in selected patients, but their modest glycemic effects and side-effect profiles make them less attractive candidates. Specific patient preferences, characteristics, susceptibilities to side effects, potential for weight gain and hypoglycemia should play a major role in drug selection.20,21 (See Supplementary Figures for adaptations of Figure 2 that address specific patient scenarios.)

Advancing to dual combination therapy. Figure 2 (and Supplementary Figures) also depicts potential sequences of escalating glucose-lowering therapy beyond metformin. If monotherapy alone does not achieve/maintain an HbA₁c target over ~ 3 months, the next step would be to add a second oral agent, a GLP-1 receptor agonist, or basal insulin.5,10 Notably, the higher the HbA₁c, the more likely insulin will be required. On average, any second agent is typically associated with an approximate further reduction in HbA₁c of ~ 1%.70,79 If no clinically meaningful glycemic reduction (i.e., “nonresponder”) is demonstrated, then, adherence having been investigated, that agent should be discontinued, and another with a different mechanism of action substituted. With a distinct paucity of long-term comparative-effectiveness trials available, uniform recommendations on the best agent to be combined with metformin cannot be made.80 Thus, advantages and disadvantages of specific drugs for each patient should be considered (Table 1).

\[ \text{HbA}_{1c} \geq 9.0\% \]

\[ \text{HbA}_{1c} \geq 10.0–12.0\% \]

\[ \text{HbA}_{1c} \geq 16.7–19.4 \text{ mmol/L (} 300–350 \text{ mg/dL) or} \]

\[ \text{HbA}_{1c} \geq 9.0\% \]

\[ \text{HbA}_{1c} \geq 10.0–12.0\% \]

\[ \text{HbA}_{1c} \geq 9.0\% \]

\[ \text{HbA}_{1c} \geq 10.0–12.0\% \]

\[ \text{HbA}_{1c} \geq 9.0\% \]

\[ \text{HbA}_{1c} \geq 10.0–12.0\% \]
Some antihyperglycemic medications lead to weight gain. This may be associated with worsening markers of insulin resistance and cardiovascular risk. One exception may be TZDs; weight gain associated with this class occurs in association with decreased insulin resistance. Although there is no uniform evidence that increases in weight in the range observed with certain therapies translate into a substantially increased cardiovascular risk, it remains important to avoid unnecessary weight gain by optimal medication selection and dose titration.

For all medications, consideration should also be given to overall tolerability. Even occasional hypoglycemia may be devastating, if severe, or merely irritating, if mild. Gastrointestinal side effects may be tolerated by some, but not others. Fluid retention may pose a clinical or merely an aesthetic problem. The risk of bone fractures may be a specific concern in postmenopausal women. It must be acknowledged that costs are a critical issue driving the selection of glucose-lowering agents in many environments. For resource-limited settings, less expensive agents should be chosen. However, due consideration should be also given to side effects and any necessary monitoring, with their own cost implications. Moreover, prevention of morbid long-term complications will likely reduce long-term expenses attributed to the disease.

Advancing to triple combination therapy. Some studies have shown advantages of adding a third noninsulin agent to a two-drug combination that is not yet or no longer achieving the glycemic target. Not surprisingly, however, at this juncture, the most robust response will usually be with insulin. Indeed, since diabetes is associated with progressive β-cell loss, many patients, especially those with long-standing disease, will eventually need to be transitioned to insulin, which should be favored in circumstances where the degree of hyperglycemia (e.g., ≥ 8.5%) makes it unlikely that another drug will be of sufficient benefit. If triple combination therapy exclusive of insulin is tried, the patient should be monitored closely, with the approach promptly reconsidered if it proves to be unsuccessful. Many months of uncontrolled hyperglycemia should specifically be avoided.

In using triple combinations the essential consideration is obviously to use agents with complementary mechanisms of action (Figure 2 and Supplementary Figures). Increasing the number of drugs heightens the potential for side effects and drug–drug interactions, raises costs, and negatively impacts patient adherence. The rationale, benefits, and side effects of each new medication should be discussed with the patient. The clinical characteristics of patients more or less likely to respond to specific combinations are, unfortunately, not well defined.

Transitions to and titrations of insulin. Most patients express reluctance to beginning injectable therapy, but, if the practitioner feels that such a transition is important, encouragement and education can usually overcome such reticence. Insulin is typically begun at a low dose (e.g., 0.1–0.2 U kg⁻¹ day⁻¹), although larger amounts (0.3–0.4 U kg⁻¹ day⁻¹) are reasonable in the more severely hyperglycemic. The most convenient strategy is with a single injection of a basal insulin, with the timing of administration dependent on the patient’s schedule and overall glucose profile (Figure 3).

Although extensive dosing instructions for insulin are beyond the scope of this statement, most patients can be taught to uptitrate their own insulin dose based on several algorithms, each essentially involving the addition of a small dose increase if hyperglycemia persists. For example, the addition of 1–2 units (or, in those already on higher doses, increments of 5–10%) to the daily dose once or twice weekly if the fasting glucose levels are above the preagreed target is a reasonable approach. As the target is neared, dosage adjustments should be more modest and occur less frequently. Downward adjustment is advisable if any hypoglycemia occurs. During self-titration, frequent contact (telephone, e-mail) with the clinician may be necessary. Practitioners themselves can, of course, also titrate basal insulin, but this would involve more intensive contact with the patient than typically available in routine clinical practice. Daily self-monitoring of blood glucose is of obvious importance during this phase. After the insulin dose is stabilized, the frequency of monitoring should be reviewed.

Consideration should be given to the addition of prandial or mealtime insulin coverage when significant postprandial glucose excursions (e.g., > 10.0 mmol/L [> 180 mg/dL]) occur. This is suggested when the fasting glucose is at target but the HbA₁c remains above goal after 3–6 months of basal insulin titration. The same would apply if large drops in glucose occur during overnight hours or in between meals, as the basal insulin dose is increased. In this scenario, the basal insulin dose would obviously need to be simultaneously decreased as prandial insulin is initiated. Although basal insulin is titrated primarily against the fasting glucose, generally irrespective of the total dose, practitioners should be aware that the need for prandial insulin therapy will become likely the more the daily dose exceeds 0.5 U kg⁻¹ day⁻¹, especially as it approaches 1 U kg⁻¹ day⁻¹. The aim with mealtime insulin is to blunt postprandial glycomic excursions, which can be extreme in some individuals, resulting in poor control during the day. Such coverage may be provided by one of two methods.

The most precise and flexible prandial coverage is possible with “basal-bolus” therapy, involving the addition of premeal rapid-acting insulin analog to ongoing basal insulin. One graduated approach is to add prandial insulin before the meal responsible for the largest glucose excursion—typically that with the greatest carbohydrate content, often, but not always, the evening meal. Subsequently, a second injection can be administered before the meal with the next largest excursion (often breakfast).
Ultimately, a third injection may be added before the smallest meal (often lunch). The actual glycemic benefits of these more advanced regimens after basal insulin are generally modest in typical patients. So, again, individualization of therapy is key, incorporating the degree of hyperglycemia needing to be addressed and the overall capacities of the patient. Importantly, data trends from self-monitoring may be particularly helpful in titrating insulins and their doses within these more advanced regimens to optimize control.

A second, perhaps more convenient but less adaptable method involves “premixed” insulin, consisting of a fixed combination of an intermediate insulin with regular insulin or a rapid analog. Traditionally, this is administered twice daily, before morning and evening meals. In general, when compared with basal insulin alone, premixed regimens tend to lower Hba1c to a larger degree, but often at the expense of slightly more hypoglycemia and weight gain. Disadvantages include the inability to titrate the shorter- from the longer-acting component of these formulations. Therefore, this strategy is somewhat inflexible but may be appropriate for certain patients who eat regularly and may be in need of a simplified approach beyond basal insulin. (An older and less commonly used variation of this two-injection strategy is known as “split-mixed,” involving a fixed amount of intermediate insulin mixed by the patient with a variable amount of regular insulin or a rapid analog. This allows for greater flexibility in dosing.)

The key messages from dozens of comparative insulin trials in type 2 diabetes include the following:
1. Any insulin will lower glucose and Hba1c.
2. All insulins are associated with some weight gain and some risk of hypoglycemia.
3. The larger the doses and the more aggressive the titration, the lower the Hba1c, but often with a greater likelihood of adverse effects.
4. Generally, long-acting insulin analogs reduce the incidence of overnight hypoglycemia, and rapid-acting insulin analogs reduce postprandial glucose excursions as compared with corresponding human insulins (NPH, Regular), but they generally do not result in clinically significantly lower Hba1c.

Metformin is often continued when basal insulin is added, with studies demonstrating less weight gain when the two are used together. Insulin secretagogues do not seem to provide for additional Hba1c reduction or prevention of hypoglycemia or weight gain after insulin is started, especially after the dose is titrated and stabilized. When basal insulin is used, continuing the secretagogue may minimize initial deterioration of glycemic control. However, secretagogues should be avoided once prandial insulin regimens are employed. TZDs should be reduced in dose (or stopped) to avoid edema and excessive weight gain, although in certain individuals with large insulin requirements from severe insulin resistance, these insulin sensitizers may be very helpful in lowering Hba1c and minimizing the required insulin dose. Data concerning the glycemic benefits of incretin-based therapy combined with basal insulin are accumulating; combination with GLP-1 receptor agonists may be helpful in some patients. Once again, the costs of these more elaborate combined regimens must be carefully considered.

Other Considerations

Age
Older adults (> 65–70 years) often have a higher atherosclerotic disease burden, reduced renal function, and more comorbidities. Many are at risk for adverse events from polypharmacy and may be both socially and economically disadvantaged. Life expectancy is reduced, especially in the presence of long-term complications. They are also more likely to be compromised by hypoglycemia; for example, unsteadiness may result in falls and fractures, and a tenuous cardiac status may deteriorate into catastrophic events. It follows that glycemic targets for elderly with long-standing or more complicated disease should be less ambitious than for the younger, healthier individuals. If lower targets cannot be achieved with simple interventions, an Hba1c of < 7.5–8.0% may be acceptable, transitioning upward as age increases and capacity for self-care, cognitive, psychological and economic status, and support systems decline.

While lifestyle modification can be successfully implemented across all age-groups, in the aged, the choice of antihyperglycemic agent should focus on drug safety, especially protecting against hypoglycemia, heart failure, renal dysfunction, bone fractures, and drug–drug interactions. Strategies specifically minimizing the risk of low blood glucose may be preferred.

In contrast, healthier patients with long life expectancy accrue risk for vascular complications over time. Therefore, lower glycemic targets (e.g., an Hba1c < 6.5–7.0%) and tighter control of body weight, blood pressure, and circulating lipids should be achieved to prevent or delay such complications. This usually requires combination therapy, the early institution of which may have the best chance of modifying the disease process and preserving quality of life.

Weight
The majority of individuals with type 2 diabetes are overweight or obese (~ 80%). In these, intensive lifestyle intervention can improve fitness, glycemic control, and cardiovascular risk factors for relatively small changes in body weight. Although insulin resistance is thought of as the predominate driver of diabetes in obese patients, they actually have a similar degree of islet dysfunction to leaner patients. Perhaps as a result, the obese may be more likely to require combination drug therapy. While common practice has favored metformin in heavier patients, because of weight loss/weight neutrality, this drug is as efficacious in lean individuals. TZDs, on the other hand, appear to be more effective in those with higher BMIs.
although their associated weight gain makes them, paradoxically, a less attractive option here. GLP-1 receptor agonists are associated with weight reduction, which in some patients may be substantial.

Bariatric surgery is an increasingly popular option in severe obesity. Type 2 diabetes frequently resolves rapidly after these procedures. The majority of patients are able to stop some, or even all, of their antihyperglycemic medications, although the durability of this effect is not known.

In lean patients, consideration should be given to the possibility of latent autoimmune diabetes in adults (LADA), a slowly progressive form of type 1 diabetes. These individuals, while presenting with mild hyperglycemia, often responsive to oral agents, eventually develop more severe hyperglycemia and require intensive insulin regimens. Measuring titres of islet-associated autoantibodies (e.g., anti-GAD) may aid their identification, encouraging a more rapid transition to insulin therapy.

Sex/racial/ethnic/genetic differences

While certain racial/ethnic features that increase the risk of diabetes are well recognized [greater insulin resistance in Latinos, more β-cell dysfunction in East Asians], using this information to craft optimal therapeutic strategies is in its infancy. This is not surprising given the polygenic inheritance pattern of the disease. Indeed, while matching a drug’s mechanism of action to the underlying causes of hyperglycemia in a specific patient seems logical, there are few data that compare strategies based on this approach. There are few exceptions, mainly involving diabetes monogenic variants often confused with type 2 diabetes, such as maturity-onset diabetes of the young (MODY), several forms of which respond preferentially to sulfonylureas. While there are no prominent sex differences in the response to various antihyperglycemic drugs, certain side effects (e.g., bone loss with TZDs) may be of greater concern in women.

Comorbidities

Coronary artery disease. Given the frequency with which type 2 diabetic patients develop atherosclerosis, optimal management strategies for those with or at high risk for coronary artery disease (CAD) are important. Since hypoglycemia may exacerbate myocardial ischemia and may cause dysrhythmias, it follows that medications that predispose patients to this adverse effect should be avoided, if possible. If they are required, however, to achieve glycemic targets, patients should be educated to minimize risk. Because of possible effects on potassium channels in the heart, certain sulfonylureas have been proposed to aggravate myocardial ischemia through effects on ischemic preconditioning, but the actual clinical relevance of this remains unproven. Metformin may have some cardiovascular benefits and would appear to be a useful drug in the setting of CAD, barring prevalent contraindications. In a single study, pioglitazone was shown to reduce modestly major adverse cardiovascular events in patients with established macrovascular disease. It may therefore also be considered, unless heart failure is present. In very preliminary reports, therapy with GLP-1 receptor agonists and DPP-4 inhibitors has been associated with improvement in either cardiovascular risk or risk factors, but there are no long-term data regarding clinical outcomes. There are very limited data suggesting that AGIs and bromocriptine may reduce cardiovascular events.

Heart failure. With an aging population and recent decreases in mortality after myocardial infarction, the diabetic patient with progressive heart failure is an increasingly common scenario. This population presents unique challenges given their polypharmacy, frequent hospitalizations, and contraindications to various agents. TZDs should be avoided. Metformin, previously contraindicated in heart failure, can now be used if the ventricular dysfunction is not severe, if patient’s cardiovascular status is not stable, and if renal function is normal. As mentioned, cardiovascular effects of incretin-based therapies, including those on ventricular function, are currently under investigation.

Chronic kidney disease. Kidney disease is highly prevalent in type 2 diabetes, and moderate to severe renal functional impairment (eGFR, 60 mL/min) occurs in approximately 20–30% of patients. The individual with progressive renal dysfunction is at increased risk for hypoglycemia, which is multifactorial. Insulin and, to some degree, the incretin hormones are eliminated more slowly, as are antihyperglycemic drugs with renal excretion. Thus, dose reduction may be necessary, contraindications need to be observed, and consequences (hypoglycemia, fluid retention, etc.) require careful evaluation.

Current U.S. prescribing guidelines warn against the use of metformin in patients with a serum creatinine ≥133 mmol/L (≥1.5 mg/dL) in men or ≥124 mmol/L (≥1.4 mg/dL) in women. Metformin is eliminated renally, and cases of lactic acidosis have been described in patients with renal failure. There is an ongoing debate, however, as to whether these thresholds are too restrictive and that those with mild–moderate renal impairment would gain more benefit than harm from using metformin. In the U.K., the National Institute for Health and Clinical Excellence (NICE) guidelines are less prescriptive and more evidence-based than those in the U.S., generally allowing use down to a GFR of 30 mL/min, with dose reduction advised at 45 mL/min. Given the current widespread reporting of estimated GFR, these guidelines appear very reasonable.

Most insulin secretagogues undergo significant renal clearance (exceptions include repaglinide and nateglinide) and the risk of hypoglycemia is therefore higher in patients with chronic kidney disease (CKD). For most of these agents, extreme caution is imperative at more severe degrees of renal dysfunction. Glyburide (known as glibenclamide in Europe), which has a prolonged duration of action and active metabolites, should be specifically avoided in this group.
Pioglitazone is not eliminated renally, and therefore there are no restrictions for use in CKD. Fluid retention may be a concern, however. Among the DPP-4 inhibitors, sitagliptin, vildagliptin, and saxagliptin share prominent renal elimination. In the face of advanced CKD, dose reduction is necessary. One exception is linagliptin, which is predominantly eliminated enterohepatically. For the GLP-1 receptor agonists exenatide is contraindicated in stage 4–5 CKD (GFR, 30 mL/min) as it is renally eliminated; the safety of liraglutide is not established in CKD though pharmacokinetic studies suggest that drug levels are unaffected as it does not require renal function for clearance.

More severe renal functional impairment is associated with slower elimination of all insulins. Thus doses need to be titrated carefully, with some awareness for the potential for more prolonged activity profiles.

Liver dysfunction. Individuals with type 2 diabetes frequently have hepatosteatosis as well as other types of liver disease. There is preliminary evidence that patients with fatty liver may benefit from treatment with pioglitazone. It should not be used in an individual with active liver disease or an alanine transaminase level above 2.5 times the upper limit of normal. In those with steatosis but milder liver test abnormalities, this insulin sensitizer may be advantageous. Sulfonylureas can rarely cause abnormalities in liver tests but are not specifically contraindicated; meglitinides can also be used. If hepatic disease is severe, secretagogues should be avoided because of the increased risk of hypoglycemia. In patients with mild hepatic disease, incretin-based drugs can be prescribed, except if there is a coexisting history of pancreatitis. Insulin has no restrictions for use in patients with liver impairment and is indeed the preferred choice in those with advanced disease.

Hypoglycemia. Hypoglycemia in type 2 diabetes was long thought to be a trivial issue, as it occurs less commonly than in type 1 diabetes. However, there is emerging concern based mainly on the results of recent clinical trials and some cross-sectional evidence of increased risk of brain dysfunction in those with repeated episodes. In the ACCORD trial, the frequency of both minor and major hypoglycemia was high in intensively managed patients—threelfold that associated with conventional therapy. It remains unknown whether hypoglycemia was the cause of the increased mortality in the intensive group. Clearly, however, hypoglycemia is more dangerous in the elderly and occurs consistently more often as glycemic targets are lowered. Hypoglycemia may lead to dysrhythmias, but can also lead to accidents and falls (which are more likely to be dangerous in the elderly), dizziness (leading to falls), confusion (so other therapies may not be taken or taken incorrectly), or infection (such as aspiration during sleep, leading to pneumonia). Hypoglycemia may be systematically underreported as a cause of death, so the true incidence may not be fully appreciated. Perhaps just as importantly, additional consequences of frequent hypoglycemia include work disability and erosion of the confidence of the patient (and that of family or caregivers) to live independently. Accordingly, in at-risk individuals, drug selection should favor agents that do not precipitate such events and, in general, blood glucose targets may need to be moderated.

Future Directions/Research Needs

For antihyperglycemic management of type 2 diabetes, the comparative evidence basis to date is relatively lean, especially beyond metformin monotherapy. There is a significant need for high-quality comparative-effectiveness research, not only regarding glycemic control, but also costs and those outcomes that matter most to patients—quality of life and the avoidance of morbidity and life-limiting complications, especially CVD. Another issue about which more data are needed is the concept of durability of effectiveness (often ascribed to β-cell preservation), which would serve to stabilize metabolic control and decrease the future treatment burden for patients. Pharmacogenetics may very well inform treatment decisions in the future, guiding the clinician to recommend a therapy for an individual patient based on predictors of response and susceptibility to adverse effects. We need more clinical data on how phenotype and other patient/disease characteristics should drive drug choices. As new medications are introduced to the type 2 diabetes pharmacopeia, their benefit and safety should be demonstrated in studies versus best current treatment, substantial enough both in size and duration to provide meaningful data on meaningful outcomes. It is appreciated, however, that head-to-head comparisons of all combinations and permutations would be impossibly large. Informed judgment and the expertise of experienced clinicians will therefore always be necessary.

Acknowledgments

This position statement was written by joint request of the ADA and the EASD Executive Committees, which have approved the final document. The process involved wide literature review, three face-to-face meetings of the Writing Group, several teleconferences, and multiple revisions via e-mail communications. We gratefully acknowledge the following experts who provided critical review of a draft of this statement: James Best, Melbourne Medical School, The University of Melbourne, Melbourne, Australia; Henk Bilo, Isala Clinics, Zwolle, the Netherlands; John Boltri, Wayne State University School of Medicine, Detroit, MI; Thomas Buchanan, Keck School of Medicine, University of Southern California, Los Angeles, CA; Paul Callaway, University of Kansas School of Medicine-Wichita, Wichita, KS; Bernard Charbonnel, University of Nantes, Nantes, France; Stephen Colagiuri, The University of Sydney, Sydney, Australia; Samuel Dagojoch, The University of Tennessee Health Science Center, Memphis, TN; Margo Farber, Detroit Medical Center, Detroit, MI; Cynthia Fritschi, College of Nursing, University of Illinois at Chicago, Chicago, IL; Rowan Hillson, The Hillingdon Hospital, Uxbridge, U.K.; Faramarz Ismail-Beigi, Case Western Reserve University School of Medicine/Cleveland VA Medical Center, Cleveland, OH; Devan Kansagara, Oregon Health & Science University/Portland VA Medical Center, Portland, OR; Ilias Migdalis, NIMTS Hospital, Athens, Greece; Donna Miller, Keck School of Medicine, University of Southern California, Los Angeles, CA; Robert Ratner, MedStar Health Research Institute/Georgetown University School of Medicine, Washington, DC; Julie Rosenstock, Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX; Guntram Schernthaner, Rudolfstiftung Hospital, Vienna, Austria; Robert Sherwin, Yale University School of Medicine.
Funding

The three face-to-face meetings and the travel of some of the writing group were supported by the EASD and ADA. D.R. Matthews acknowledges support from the National Institute for Health Research.

Duality of interest

During the past 12 months, the following relationships with companies whose products or services directly relate to the subject matter in this document are declared:

R.M. Bergenstal: membership of scientific advisory boards and consultation for or clinical research support with Abbott Diabetes Care, Amylin, Bayer, Becton Dickinson, Boehringer Ingelheim, Bristol-Myers Squibb, DarioMed, Eli Lilly, Halozyme, Helmsley Trust, Hygeia, Johnson & Johnson, Medtronic, NIH, Novo Nordisk, Roche, Sanofi, and Takeda (all under contracts with his employer). Inherited stock in Merck (held by family)

J.B. Buse: research and consulting with Amylin Pharmaceuticals, Inc.; AstraZeneca; BioInel Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Diartis Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Halozyme Therapeutics; Johnson & Johnson; Medtronic MiniMed; Merck & Co., Inc.; Novo Nordisk; Pfizer Inc.; Sanofi; and TransPharma Medical Ltd (all under contracts with his employer)

M. Diamant: member of advisory boards of Abbott Diabetes Care, Eli Lilly, Merck Sharp & Dohme (MSD), Novo Nordisk, Poxel Pharma. Consultancy for: Astra-BMS, Sanofi. Speaker engagements: Eli Lilly, MSD, Novo Nordisk. Through Dr. Diamant, the VU University receives research grants from Amylin/Eli Lilly, MSE, Novo Nordisk, Sanofi (all under contracts with the Institutional Research Foundation)

E. Ferrannini: membership on scientific advisory boards or speaking engagements for: Merck Sharp & Dohme, Boehringer Ingelheim, GlaxoSmithKline, BMS/ AstraZeneca, Eli Lilly & Co., Novartis, Sanofi. Research grant support from: Eli Lilly & Co. and Boehringer Ingelheim

S.E. Inzucchi: advisory consultant to: Merck, Takeda, Boehringer Ingelheim. Research funding or supplies to Yale University: Eli Lilly, Takeda. Participation in medical educational projects, for which unrestricted funding from Amylin, Eli Lilly, Boehringer Ingelheim, Merck, Novo Nordisk, and Takeda was provided by Yale University

D.R. Matthews: has received advisory board consulting fees or honoraria from Novo Nordisk, GlaxoSmithKline, Novartis, Eli Lilly, Johnson & Johnson, and Servier. He has research support from Johnson & Johnson and Merck Sharp & Dohme. He has lectured for Novo Nordisk, Servier, and Novartis

M. Nauck: has received research grants (to his institution) from AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., Merck Sharp & Dohme, Novartis Pharma, GlaxoSmithKline, Novo Nordisk, Roche, and Takeda. He has received consulting and travel fees or honoraria for speaking from AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Bristol-Myers Squibb, Diartis, Eli Lilly & Co., F. Hoffmann-La Roche Ltd, Intarcia Therapeutics, Merck Sharp & Dohme, Novo Nordisk, Sanofi-Aventis Pharma, and Takeda

A.L. Peters: has received lecturing fees and/or for ad hoc consulting from Amylin, Lilly, Novo Nordisk, Sanofi, Takeda, Boehringer Ingelheim

A. Tsapas: has received travel grant, educational grant, research grant and lecture fees from Merck Serono, Novo Nordisk, and Novartis, respectively

R. Wender: declares he has no duality of interest

Contribution statement

All the named writing group authors contributed substantially to the document including each writing part of the text. They were at the face-to-face meetings and teleconferences. All authors supplied detailed input and approved the final version. S.E. Inzucchi and D.R. Matthews directed, chaired, and coordinated the input with multiple e-mail exchanges between all participants.

References


14 NICE. Type 2 Diabetes: The Management of Type 2 Diabetes: NICE Clinical Guideline 87. National Institute for Health and Clinical Excellence, 2009


Position Statement


19 Glasgow RE, Peeples M, Skovlund SE. Is the patient in the diabetes performance measures? The case for including patient-centered and self-management measures. Diabetes Care 2008;31:1046–1050


41 Groop LC, Ferrannini E. Insulin action and substrate competition. Baillieres Clin Endocrinol Metab 1993;7:1007–1032


44 Lee SJ, Eng C. Goals of glycemic control in frail older patients with diabetes. JAMA 2011;305:1350–1351


46 May C, Montori VM, Mair FS. We need minimally disruptive medicine. BMJ 2009;339:b2803


**Position Statement**


Van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, de Graaf WJ. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. *Cochrane Database Syst Rev* 2006;Issue 4.(CD005061. DOI: 10.1002/14651858.CD005061.pub2


Cryer PE. Hypoglycemia: the limiting factor in the glycemic management of Type I and Type II diabetes. *Diabetologia* 2002;45:937–948


Riddle MC. The Treat-to-Target Trial and related studies. *Endocr Pract* 2006;12(Suppl. 1):71–79


Garber AJ. The importance of titrating starting insulin regimens in patients with type 2 diabetes. *Diabetes Obes Metab* 2009;11(Suppl. 5):10–13


Raccab D. Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus. *Diabetes Obes Metab* 2008;10(Suppl. 2):76–82


Vilsboll T, Rosenstock J, Yki-Jarvinen H, et al. Efficacy and safety of sitagliptin when


123 Holstein A, Stumvoll M. Contraindications can damage your health—is metformin a case in point? *Diabetologia* 2005;48:2454–2459


126 Ong YP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. *Clin Liver Dis* 2007;11:1–16, vii


132 Berrie HD, Garwood CL. Diabetes medications related to an increased risk of falls and fall-related morbidity in the elderly. *Ann Pharmacother* 2010;44:712–717
